OSLO, Norway, June 16, 2026
SonoClear AS has announced that findings from its pivotal multicenter study evaluating the SonoClear® System Acoustic Coupling Fluid during glioma surgery have been selected for oral presentation at the European Association of Neurosurgical Societies (EANS) 2026 Annual Congress. The presentation, titled “An Acoustic Coupling Fluid Improves Intraoperative Ultrasound Image Quality During Glioma Surgery: Results of a Pivotal Multicenter Study,” will be delivered by internationally recognized neurosurgeon Professor Francesco DiMeco during the congress in Hamburg, Germany. The acceptance of the study for oral presentation at one of the world’s leading neurosurgical meetings highlights growing scientific and clinical interest in technologies designed to improve intraoperative ultrasound imaging and support more accurate brain tumor surgery. With more than 2,000 neurosurgeons and neuroscience specialists expected to attend EANS 2026, the study is expected to attract significant attention from the global neuro-oncology and surgical imaging communities.
Pivotal Study Demonstrates Improved Ultrasound Image Quality
The pivotal multicenter study investigated the effectiveness of the SonoClear® System, a novel acoustic coupling fluid engineered to enhance ultrasound visualization during brain tumor resections. Intraoperative ultrasound is widely used by neurosurgeons to identify tumor boundaries and guide surgical decision-making in real time. However, traditional irrigation fluids such as saline can create acoustic artifacts within the surgical cavity, generating image distortion and visual noise that may compromise image interpretation. The SonoClear System was specifically developed to address this challenge by matching the acoustic properties of brain tissue and minimizing artifact formation during imaging procedures.
According to the study, the technology demonstrated the potential to improve image quality during glioma surgery by reducing cavity-related artifacts and enhancing visualization of critical anatomical structures. Improved image clarity may support more precise assessment of residual tumor tissue and help surgeons make more informed intraoperative decisions. The results represent an important advancement in efforts to improve the performance of ultrasound-guided neurosurgical procedures.
Innovative Technology Targets Critical Need in Brain Tumor Surgery
Advertisement
Brain tumor surgery remains one of the most technically demanding areas of modern medicine, where accurate differentiation between tumor tissue and healthy brain structures is essential for maximizing resection while preserving neurological function. The SonoClear® System consists of a sterile, biocompatible, bio-excretable acoustic coupling fluid designed specifically for use during brain tumor operations. By reducing ultrasound artifacts within the resection cavity, the technology aims to provide surgeons with a clearer and more reliable view of the surgical field throughout the procedure.
Enhanced visualization may contribute to improved tumor removal rates, reduced residual disease, and potentially better long-term patient outcomes. The technology has already received FDA Breakthrough Device designation, recognizing its potential to address unmet clinical needs in neurosurgical imaging. Although the system is not yet commercially available, continued clinical evaluation and scientific validation are supporting its advancement toward regulatory and commercial milestones.
Growing Clinical Interest Supports Future Commercialization Strategy
The selection of the SonoClear study for oral presentation at EANS 2026 reflects increasing momentum behind advanced imaging technologies designed to improve surgical precision. The company believes the findings further validate the clinical value of artifact reduction during intraoperative ultrasound-guided procedures and strengthen the case for broader adoption following regulatory clearance. Gliomas and other brain tumors continue to present significant treatment challenges, with surgical outcomes often dependent on the ability to accurately visualize tumor margins during resection. Industry experts increasingly view image-enhancing technologies as important tools for improving operative performance and supporting personalized neurosurgical care.
As SonoClear continues preparations for commercialization, the company is actively pursuing strategic initiatives aimed at facilitating global market access and clinical adoption. With growing interest from surgeons, researchers, and healthcare institutions, the pivotal study results presented at EANS 2026 could represent an important step toward establishing the SonoClear System as a valuable innovation in image-guided brain tumor surgery.
Source: SonoClear press release
